Oral semaglutide helps type 2 diabetes in patients with fatty liver disease linked to metabolism

Significant improvements in body weight, liver enzymes, and glycaemic control were observed in 70 patients after 48 weeks of oral semaglutide treatment.

• Body weight, liver enzymes, lipid profile, and glycaemic control showed significant enhancement after 48 weeks (all p < 0.01).
• Controlled attenuation parameter values decreased significantly from baseline to 48 weeks (p < 0.01).
• Changes in alanine aminotransferase and controlled attenuation parameter values were significantly correlated with changes in body weight (both p < 0.01).
• Markers of liver fibrosis, including type IV collagen 7S and liver stiffness measurement, significantly decreased over the treatment period (all p < 0.01).
• The most common adverse events were Grades 1-2 gastrointestinal symptoms, with nausea occurring in 28.8% of patients.

Simplified